Official ESCRS | European Society of Cataract & Refractive Surgeons

 

Additional correction using LASIK and PRK on pseudophakic eyes depending on the type of implanted IOL

Search Title by author or title

Session Details

Session Title: Presented Poster Session: Keratorefractive Surgery Results I

Venue: Poster Village: Pod 2

First Author: : L.Batalina RUSSIA

Co Author(s): :    N. Pashinova   E. Gurmizov   K. Pershin   A. Tsygankov              

Abstract Details

Purpose:

Analysis of the results of the additional correction of residual ametropia using LASIK and PRK on pseudophakic eyes, depending on the type of previously implanted IOL.

Setting:

Eximer eye center (Moscow, St. Petersburg).

Methods:

The prospective open study included 57 patients (79 eyes) with the implantation of various IOL models. Of the total number of patients, men accounted for 45.6%, women - 54.5%. The average age of patients was 50.8 ± 13.9 years. LASIK (n​​=72;91.1%) and PRK (n=7;8.9%) were carried out. In 6 cases, femtolaser support was performed. Target refraction ranged from -0.25 to 0.25 D in most (97.5%) cases. Group I (spherical and aspherical monofocal IOL, 38 eyes) and group II (multifocal IOL, 39 eyes) were determined. The follow-up period was 6 to 9 months.

Results:

The studied groups were comparable with the exception of Cyl (-1.45±0.43 in group I and -0.4±0.29 in group II, p=0.046). In group I, there was a statistically significant  increase in UCFVA from 0.31±0.14 to 0.72±0.22. The target refraction was achieved in 94.8% of cases (n=36). A significant  decrease in Cyl was noted after 6 months of follow-up (-1.45±0.43 D and -0.18±0.80 D, respectively). In group II a similar dynamics of UCFVA was observed (0.43±0.17 and 0.80± 0.18, respectively, p<0.05). Target refraction was achieved in 90.8% of cases (n=36).

Conclusions:

The possibility of using LASIK and PRK for the additional correction of residual ametropia in pseudophakic eyes is shown. The effectiveness of the method for achieving the target UCFVA did not depend on the type of implanted IOL. Differences are shown only for the cylindrical equivalent.

Financial Disclosure:

None

Back to previous